StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research report released on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Trading Up 1.0 %
Shares of Pulmatrix stock opened at $2.02 on Friday. The stock has a 50-day moving average price of $2.06 and a 200 day moving average price of $2.03. The company has a market cap of $7.38 million, a P/E ratio of -0.84 and a beta of 1.00. Pulmatrix has a 1 year low of $1.55 and a 1 year high of $2.75.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. The business had revenue of $1.55 million during the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Further Reading
- Five stocks we like better than Pulmatrix
- Stock Average Calculator
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the Nikkei 225 index?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Using the MarketBeat Dividend Tax Calculator
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
